Avanir Pharmaceuticals Inc (AVNR) 16.96 $AVNR A
Post# of 273257
Posted On: 09/04/2016 3:09:29 AM
Avanir Pharmaceuticals Inc (AVNR) 16.96 $AVNR
Avanir Pharmaceuticals to Present Data on ONZETRA(TM) Xsail(TM) at American Headache Society (AHS) 2016 Annual Scientific Meeting
PR Newswire - Thu Jun 09, 4:30PM CDT
Avanir Pharmaceuticals, Inc. today announced that the company will be presenting results from several studies about ONZETRA(TM) Xsail(TM) (sumatriptan nasal powder) 11 mg per nose piece, formerly AVP-825, at the 58th American Headache Society Annual Scientific Meeting being held in San Diego from June 9-12, 2016. ONZETRA Xsail was approved by the U.S. Food and Drug Administration (FDA) in January 2016 and is now available for prescription for the acute treatment of migraine with or without aura in adults.
AVNR: 16.96 (unch)
NUEDEXTA® Effective for Pseudobulbar Affect (PBA) in Patients with Alzheimer's Disease and other Dementias, Stroke and Traumatic Brain Injury
PR Newswire - Wed Jun 08, 7:00PM CDT
Avanir Pharmaceuticals, Inc. today announced the publication of full results from the PRISM II study, which demonstrated significant improvement of pseudobulbar affect (PBA) following treatment with NUEDEXTA® (dextromethorphan hydrobromide/quinidine sulfate) capsules in patients with Alzheimer's disease (AD) and other dementias, stroke and traumatic brain injury (TBI). The study was published online in BMC Neurology.
AVNR: 16.96 (unch)
AVANIR Pharmaceuticals Announces U.S. Launch and Availability of ONZETRA(TM) Xsail(TM) for the Acute Treatment of Migraine in Adults
PR Newswire - Mon May 16, 8:00AM CDT
Avanir Pharmaceuticals, Inc. today announced ONZETRA(TM) Xsail(TM) (sumatriptan nasal powder) is now available by prescription in U.S. pharmacies.
AVNR: 16.96 (unch)
Avanir Pharmaceuticals to Present Data on NUEDEXTA® and ONZETRA(TM) Xsail(TM) at American Academy of Neurology (AAN) 2016 Annual Meeting
PR Newswire - Fri Apr 15, 4:19PM CDT
Furthering its commitment to developing treatments for central nervous system disorders, Avanir Pharmaceuticals, Inc. today announced that data from the PRISM II study of NUEDEXTA® (dextromethorphan hydrobromide/quinidine sulfate) capsules for the treatment of pseudobulbar affect (PBA) and multiple data presentations on the use of ONZETRA(TM) Xsail(TM) (formerly AVP-825), which was approved by the FDA in January for the acute treatment of migraine with or without aura in adults, will be presented at the 68th American Academy of Neurology (AAN) Annual Meeting being held April 15-21 in Vancouver, British Columbia, Canada.
AVNR: 16.96 (unch)
Avanir Pharmaceuticals Announces FDA Approval of ONZETRA(TM) Xsail(TM) (AVP-825) for the Acute Treatment of Migraine in Adults
PR Newswire - Thu Jan 28, 4:13PM CST
Avanir Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved ONZETRA(TM) Xsail(TM) (sumatriptan nasal powder), formerly known as AVP-825, for the acute treatment of migraine with or without aura in adults. ONZETRA Xsail is an intranasal medication delivery system consisting of a low-dose (22mg) of sumatriptan powder that is delivered utilizing the novel Xsail(TM) Breath Powered Delivery Device. ONZETRA Xsail is a fast-acting dry powder formulation of sumatriptan, the most commonly prescribed migraine medication.
AVNR: 16.96 (unch)
Avanir Pharmaceuticals Announces Publication of Study Evaluating the Prevalence of Pseudobulbar Affect (PBA) Symptoms and Use of Antipsychotic Medications in Nursing Homes
PR Newswire - Tue Dec 01, 7:30AM CST
Avanir Pharmaceuticals, Inc. today announced that data on the prevalence of symptoms for pseudobulbar affect (PBA), a distressing condition characterized by sudden and uncontrollable outbursts of laughing and/or crying resulting from certain neurologic diseases or brain injury (TBI), and the use of antipsychotic medications in nursing home residents, were recently published in the International Journal of Geriatric Psychiatry. The study showed that almost one in 10 (9.0%) nursing home residents had symptoms suggestive of PBA and that patients with PBA symptoms were twice as likely to be receiving antipsychotic medications (p=0.015) even though patients with the diagnosis of psychosis were excluded from the sample assessed. In a subset of these residents who had neurological disorders affecting the brain, 17.5% were found to have symptoms suggestive of PBA.
AVNR: 16.96 (unch)
Avanir Pharmaceuticals Announces Initiation of Phase III Trial of AVP-786 for Agitation in Patients with Alzheimer's Disease
PR Newswire - Mon Nov 16, 7:00AM CST
Avanir Pharmaceuticals, Inc. today announced initiation of enrollment into a phase III clinical trial evaluating AVP-786 for the treatment of agitation in patients with Alzheimer's disease. This is the first of two placebo-controlled phase III trials in the company's TRIAD(TM) program. Avanir Pharmaceuticals recently received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the development of AVP-786 for this indication.
AVNR: 16.96 (unch)
Avanir Pharmaceuticals Prevails in NUEDEXTA® Patent Appeal Maintaining Exclusivity Through 2026
PR Newswire - Tue Aug 11, 7:30AM CDT
Avanir Pharmaceuticals, Inc. today announced that a panel of the U.S. Court of Appeals for the Federal Circuit has upheld the validity and enforceability of Avanir's patents covering NUEDEXTA (U.S. Patent Nos. 7,659,282 (the '282' patent) and 8,227,484 (the '484' patent)). The decision confirms patent protection for NUEDEXTA until 2026 in the United States.
AVNR: 16.96 (unch)
Avanir Pharmaceuticals Announces New Findings from Dementia/Alzheimer's Disease Cohort of PRISM II Study at Alzheimer's Association International Conference
PR Newswire - Thu Jul 23, 7:30AM CDT
Avanir Pharmaceuticals, Inc. today announced new findings from the dementia/Alzheimer's disease cohort of the PRISM II study, a phase IV study evaluating the safety and effectiveness of NUEDEXTA® in treating pseudobulbar affect (PBA) in patients with dementia/Alzheimer's disease, stroke and traumatic brain injury (TBI). PBA is a distressing condition characterized by sudden and uncontrollable outbursts of laughing and/or crying resulting from certain neurologic diseases or brain injury. The data were presented at the 2015 Alzheimer's Association International Conference (AAIC) in Washington, D.C., along with two additional presentations related to Avanir's program in agitation secondary to Alzheimer's disease.
AVNR: 16.96 (unch)
/C O R R E C T I O N -- Avanir Pharmaceuticals, Inc./
PR Newswire - Tue Jun 30, 7:47PM CDT
In the news release, Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study, issued 30-Jun-2015 by Avanir Pharmaceuticals, Inc. over PR Newswire, we are advised by the company that there were multiple changes in the fourth paragraph, third bullet, second subbullet and fifth paragraph, third bullet, second subbullet, as originally issued inadvertently. The complete, corrected release follows:
AVNR: 16.96 (unch)
Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study
PR Newswire - Tue Jun 30, 8:00AM CDT
Avanir Pharmaceuticals, Inc. today announced top-line data from the PRISM II study showing that treatment with NUEDEXTA® was associated with a statistically significant reduction in symptoms of pseudobulbar affect (PBA) in patients with traumatic brain injury (TBI) or stroke. PBA is a distressing condition characterized by sudden and uncontrollable outbursts of laughing and/or crying resulting from certain neurologic diseases or brain injury. PRISM II is a phase IV study evaluating the safety and effectiveness of NUEDEXTA in treating PBA in patients with dementia/Alzheimer's disease, stroke and TBI. Data from patients with PBA secondary to TBI were presented Monday, June 29th at the 33rd Annual Symposium of the National Neurotrauma Society in Santa Fe, New Mexico. Data from patients with PBA secondary to dementia/Alzheimer's disease were presented at last year's American Neurological Association Meeting, and full results from the stroke cohort will be presented at a future date.
AVNR: 16.96 (unch)
Avanir Pharmaceuticals Announces Publication of Positive Phase IIIb Results from AVP-825 Head-to-Head COMPASS Study in the Journal "Headache"
PR Newswire - Wed Jun 17, 8:00AM CDT
Avanir Pharmaceuticals, Inc. today announced that COMPASS, its Phase IIIb, cross-over clinical trial comparing the efficacy and safety of AVP-825 22mg to sumatriptan 100mg tablets for the treatment of acute migraine across multiple attacks, has been published and is available in hard copy at the 57th Annual Scientific Meeting of the American Headache Society (AHS) in Washington, DC. AVP-825 is an investigational drug-device combination product consisting of low-dose sumatriptan powder delivered intranasally utilizing a novel Breath Powered(TM) delivery technology. A New Drug Application (NDA) for AVP-825 has been accepted and is currently under review by the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) goal date of November 6, 2015.
AVNR: 16.96 (unch)
Avanir Pharmaceuticals Announces Presentation of Survey Evaluating the Prevalence of Pseudobulbar Affect (PBA) Symptoms in Retired Professional Football Players at the 12th Annual North American Brain Injury Society Conference
PR Newswire - Tue May 05, 8:00AM CDT
Avanir Pharmaceuticals, Inc. today announced the presentation of survey results assessing the prevalence and impact of pseudobulbar affect (PBA) symptoms in former professional football players. The survey showed that nearly all players had experienced head trauma or injury during their football career, and that one-third experience symptoms suggestive of a little known but treatable consequence of head injury called PBA. The survey results were presented at the 12th Annual North American Brain Injury Society (NABIS) Conference in San Antonio, TX on April 29 - May 2, 2015. An estimated two million Americans suffer from PBA, a distressing neurologic condition characterized by uncontrollable, sudden outbursts of crying and/or laughing in patients with underlying neurologic disease or brain injury.
AVNR: 16.96 (unch)
Danny Glover Joins PBA Facts Campaign, to Educate and Build Awareness of Pseudobulbar Affect (PBA), a Little Known but Widespread Neurologic Condition
PR Newswire - Fri May 01, 8:00AM CDT
Legendary actor and director Danny Glover joins Avanir Pharmaceuticals, Inc. in a new PBAFacts campaign designed to educate and encourage patients with neurologic conditions, and their caregivers, to learn more about Pseudobulbar Affect (PBA) and to speak with their physician. The campaign hinges on the idea that an actor has the ability to cry and laugh on cue and how that contrasts with the lack of control experienced by people living with PBA episodes.
AVNR: 16.96 (unch)
Avanir Pharmaceuticals Announces Multiple Data Presentations Highlighting Its Central Nervous System (CNS) Therapeutics Franchise at the American Academy of Neurology (AAN) 2015 Annual Meeting
PR Newswire - Wed Apr 15, 8:55AM CDT
Avanir Pharmaceuticals, Inc. today announced that data highlighting its central nervous system (CNS) therapeutics franchise, including data from the Phase 2 study of AVP-923 for the treatment of agitation in Alzheimer's disease, data from the Alzheimer's cohort of PRISM II of NUEDEXTA® for the treatment of Pseudobulbar Affect (PBA) and several data presentations on the use of AVP-825 for the treatment of acute migraine, will be presented at the American Academy of Neurology (AAN) Annual Meeting being held at the Walter E. Washington Convention Center in Washington, D.C., April 18-25, 2015.
AVNR: 16.96 (unch)
Football Hall-of-Famer Barry Sanders Tackles Pseudobulbar Affect; A Little-known But Widespread Condition Caused by Brain Injury
PR Newswire - Wed Jan 21, 6:30AM CST
New research shows 99 percent of former professional football players surveyed by the Gridiron Greats Assistance Fund, Inc., have suffered a head injury, repeated concussions, or a blow to the head sometime during their football career. More concerning is that a third of these players admit to experiencing symptoms consistent with a little-known neurological condition caused by brain injury called Pseudobulbar Affect (PBA); and most were unaware that PBA symptoms may result from head injury. To help educate the community, legendary football Hall-of-Famer, Barry Sanders, has teamed up with Gridiron Greats and Avanir Pharmaceuticals, Inc. to launch Tackle PBA, a new educational campaign to increase awareness of PBA as a potential consequence of brain injury.
AVNR: 16.96 (unch)
The Surprising Thing Most of 2014's Top 10 Stocks Have in Common
Keith Speights, The Motley Fool - Motley Fool - Sun Jan 11, 9:03AM CST
Are you good at spotting patterns? Most of us are. We even spot patterns when they're really not there -- like seeing faces in clouds. The list below of 2014's top 10 stocks with a market cap above $300 million, however, reveals a very real pattern...
AVNR: 16.96 (unch), NPSP: 45.97 (+0.01), AGIO: 36.35 (-0.39), CELG: 105.49 (-0.88), EXEL: 11.54 (+0.19)
Avanir reports 4Q loss
Automated Insights - Mon Jan 05, 1:46PM CST
ALISO VIEJO, Calif. (AP) _ Avanir Pharmaceuticals Inc. (AVNR) on Wednesday said its loss narrowed to $14.1 million in its fiscal fourth quarter.
AVNR: 16.96 (unch)
The Market's Top 10 Stocks of 2014
Dan Caplinger, The Motley Fool - Motley Fool - Sat Jan 03, 8:00AM CST
For six years now, investors have looked with skepticism at the rise in the stock market. And for a sixth straight year, the markets defied those who were waiting for a major downturn to invest, with the S&P 500 climbing about 14% including...
BLUE: 49.05 (-0.28), TTPH: 3.72 (-0.06), AVNR: 16.96 (unch), SWKS: 74.62 (-0.47), CMRX: 4.62 (unch), ACHN: 8.12 (-0.11), HA: 47.60 (+0.31), RCPT: 231.96 (-0.03), PTCT: 7.91 (+0.12), AGIO: 36.35 (-0.39)
Avanir Pharmaceuticals to Present Data on ONZETRA(TM) Xsail(TM) at American Headache Society (AHS) 2016 Annual Scientific Meeting
PR Newswire - Thu Jun 09, 4:30PM CDT
Avanir Pharmaceuticals, Inc. today announced that the company will be presenting results from several studies about ONZETRA(TM) Xsail(TM) (sumatriptan nasal powder) 11 mg per nose piece, formerly AVP-825, at the 58th American Headache Society Annual Scientific Meeting being held in San Diego from June 9-12, 2016. ONZETRA Xsail was approved by the U.S. Food and Drug Administration (FDA) in January 2016 and is now available for prescription for the acute treatment of migraine with or without aura in adults.
AVNR: 16.96 (unch)
NUEDEXTA® Effective for Pseudobulbar Affect (PBA) in Patients with Alzheimer's Disease and other Dementias, Stroke and Traumatic Brain Injury
PR Newswire - Wed Jun 08, 7:00PM CDT
Avanir Pharmaceuticals, Inc. today announced the publication of full results from the PRISM II study, which demonstrated significant improvement of pseudobulbar affect (PBA) following treatment with NUEDEXTA® (dextromethorphan hydrobromide/quinidine sulfate) capsules in patients with Alzheimer's disease (AD) and other dementias, stroke and traumatic brain injury (TBI). The study was published online in BMC Neurology.
AVNR: 16.96 (unch)
AVANIR Pharmaceuticals Announces U.S. Launch and Availability of ONZETRA(TM) Xsail(TM) for the Acute Treatment of Migraine in Adults
PR Newswire - Mon May 16, 8:00AM CDT
Avanir Pharmaceuticals, Inc. today announced ONZETRA(TM) Xsail(TM) (sumatriptan nasal powder) is now available by prescription in U.S. pharmacies.
AVNR: 16.96 (unch)
Avanir Pharmaceuticals to Present Data on NUEDEXTA® and ONZETRA(TM) Xsail(TM) at American Academy of Neurology (AAN) 2016 Annual Meeting
PR Newswire - Fri Apr 15, 4:19PM CDT
Furthering its commitment to developing treatments for central nervous system disorders, Avanir Pharmaceuticals, Inc. today announced that data from the PRISM II study of NUEDEXTA® (dextromethorphan hydrobromide/quinidine sulfate) capsules for the treatment of pseudobulbar affect (PBA) and multiple data presentations on the use of ONZETRA(TM) Xsail(TM) (formerly AVP-825), which was approved by the FDA in January for the acute treatment of migraine with or without aura in adults, will be presented at the 68th American Academy of Neurology (AAN) Annual Meeting being held April 15-21 in Vancouver, British Columbia, Canada.
AVNR: 16.96 (unch)
Avanir Pharmaceuticals Announces FDA Approval of ONZETRA(TM) Xsail(TM) (AVP-825) for the Acute Treatment of Migraine in Adults
PR Newswire - Thu Jan 28, 4:13PM CST
Avanir Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved ONZETRA(TM) Xsail(TM) (sumatriptan nasal powder), formerly known as AVP-825, for the acute treatment of migraine with or without aura in adults. ONZETRA Xsail is an intranasal medication delivery system consisting of a low-dose (22mg) of sumatriptan powder that is delivered utilizing the novel Xsail(TM) Breath Powered Delivery Device. ONZETRA Xsail is a fast-acting dry powder formulation of sumatriptan, the most commonly prescribed migraine medication.
AVNR: 16.96 (unch)
Avanir Pharmaceuticals Announces Publication of Study Evaluating the Prevalence of Pseudobulbar Affect (PBA) Symptoms and Use of Antipsychotic Medications in Nursing Homes
PR Newswire - Tue Dec 01, 7:30AM CST
Avanir Pharmaceuticals, Inc. today announced that data on the prevalence of symptoms for pseudobulbar affect (PBA), a distressing condition characterized by sudden and uncontrollable outbursts of laughing and/or crying resulting from certain neurologic diseases or brain injury (TBI), and the use of antipsychotic medications in nursing home residents, were recently published in the International Journal of Geriatric Psychiatry. The study showed that almost one in 10 (9.0%) nursing home residents had symptoms suggestive of PBA and that patients with PBA symptoms were twice as likely to be receiving antipsychotic medications (p=0.015) even though patients with the diagnosis of psychosis were excluded from the sample assessed. In a subset of these residents who had neurological disorders affecting the brain, 17.5% were found to have symptoms suggestive of PBA.
AVNR: 16.96 (unch)
Avanir Pharmaceuticals Announces Initiation of Phase III Trial of AVP-786 for Agitation in Patients with Alzheimer's Disease
PR Newswire - Mon Nov 16, 7:00AM CST
Avanir Pharmaceuticals, Inc. today announced initiation of enrollment into a phase III clinical trial evaluating AVP-786 for the treatment of agitation in patients with Alzheimer's disease. This is the first of two placebo-controlled phase III trials in the company's TRIAD(TM) program. Avanir Pharmaceuticals recently received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the development of AVP-786 for this indication.
AVNR: 16.96 (unch)
Avanir Pharmaceuticals Prevails in NUEDEXTA® Patent Appeal Maintaining Exclusivity Through 2026
PR Newswire - Tue Aug 11, 7:30AM CDT
Avanir Pharmaceuticals, Inc. today announced that a panel of the U.S. Court of Appeals for the Federal Circuit has upheld the validity and enforceability of Avanir's patents covering NUEDEXTA (U.S. Patent Nos. 7,659,282 (the '282' patent) and 8,227,484 (the '484' patent)). The decision confirms patent protection for NUEDEXTA until 2026 in the United States.
AVNR: 16.96 (unch)
Avanir Pharmaceuticals Announces New Findings from Dementia/Alzheimer's Disease Cohort of PRISM II Study at Alzheimer's Association International Conference
PR Newswire - Thu Jul 23, 7:30AM CDT
Avanir Pharmaceuticals, Inc. today announced new findings from the dementia/Alzheimer's disease cohort of the PRISM II study, a phase IV study evaluating the safety and effectiveness of NUEDEXTA® in treating pseudobulbar affect (PBA) in patients with dementia/Alzheimer's disease, stroke and traumatic brain injury (TBI). PBA is a distressing condition characterized by sudden and uncontrollable outbursts of laughing and/or crying resulting from certain neurologic diseases or brain injury. The data were presented at the 2015 Alzheimer's Association International Conference (AAIC) in Washington, D.C., along with two additional presentations related to Avanir's program in agitation secondary to Alzheimer's disease.
AVNR: 16.96 (unch)
/C O R R E C T I O N -- Avanir Pharmaceuticals, Inc./
PR Newswire - Tue Jun 30, 7:47PM CDT
In the news release, Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study, issued 30-Jun-2015 by Avanir Pharmaceuticals, Inc. over PR Newswire, we are advised by the company that there were multiple changes in the fourth paragraph, third bullet, second subbullet and fifth paragraph, third bullet, second subbullet, as originally issued inadvertently. The complete, corrected release follows:
AVNR: 16.96 (unch)
Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study
PR Newswire - Tue Jun 30, 8:00AM CDT
Avanir Pharmaceuticals, Inc. today announced top-line data from the PRISM II study showing that treatment with NUEDEXTA® was associated with a statistically significant reduction in symptoms of pseudobulbar affect (PBA) in patients with traumatic brain injury (TBI) or stroke. PBA is a distressing condition characterized by sudden and uncontrollable outbursts of laughing and/or crying resulting from certain neurologic diseases or brain injury. PRISM II is a phase IV study evaluating the safety and effectiveness of NUEDEXTA in treating PBA in patients with dementia/Alzheimer's disease, stroke and TBI. Data from patients with PBA secondary to TBI were presented Monday, June 29th at the 33rd Annual Symposium of the National Neurotrauma Society in Santa Fe, New Mexico. Data from patients with PBA secondary to dementia/Alzheimer's disease were presented at last year's American Neurological Association Meeting, and full results from the stroke cohort will be presented at a future date.
AVNR: 16.96 (unch)
Avanir Pharmaceuticals Announces Publication of Positive Phase IIIb Results from AVP-825 Head-to-Head COMPASS Study in the Journal "Headache"
PR Newswire - Wed Jun 17, 8:00AM CDT
Avanir Pharmaceuticals, Inc. today announced that COMPASS, its Phase IIIb, cross-over clinical trial comparing the efficacy and safety of AVP-825 22mg to sumatriptan 100mg tablets for the treatment of acute migraine across multiple attacks, has been published and is available in hard copy at the 57th Annual Scientific Meeting of the American Headache Society (AHS) in Washington, DC. AVP-825 is an investigational drug-device combination product consisting of low-dose sumatriptan powder delivered intranasally utilizing a novel Breath Powered(TM) delivery technology. A New Drug Application (NDA) for AVP-825 has been accepted and is currently under review by the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) goal date of November 6, 2015.
AVNR: 16.96 (unch)
Avanir Pharmaceuticals Announces Presentation of Survey Evaluating the Prevalence of Pseudobulbar Affect (PBA) Symptoms in Retired Professional Football Players at the 12th Annual North American Brain Injury Society Conference
PR Newswire - Tue May 05, 8:00AM CDT
Avanir Pharmaceuticals, Inc. today announced the presentation of survey results assessing the prevalence and impact of pseudobulbar affect (PBA) symptoms in former professional football players. The survey showed that nearly all players had experienced head trauma or injury during their football career, and that one-third experience symptoms suggestive of a little known but treatable consequence of head injury called PBA. The survey results were presented at the 12th Annual North American Brain Injury Society (NABIS) Conference in San Antonio, TX on April 29 - May 2, 2015. An estimated two million Americans suffer from PBA, a distressing neurologic condition characterized by uncontrollable, sudden outbursts of crying and/or laughing in patients with underlying neurologic disease or brain injury.
AVNR: 16.96 (unch)
Danny Glover Joins PBA Facts Campaign, to Educate and Build Awareness of Pseudobulbar Affect (PBA), a Little Known but Widespread Neurologic Condition
PR Newswire - Fri May 01, 8:00AM CDT
Legendary actor and director Danny Glover joins Avanir Pharmaceuticals, Inc. in a new PBAFacts campaign designed to educate and encourage patients with neurologic conditions, and their caregivers, to learn more about Pseudobulbar Affect (PBA) and to speak with their physician. The campaign hinges on the idea that an actor has the ability to cry and laugh on cue and how that contrasts with the lack of control experienced by people living with PBA episodes.
AVNR: 16.96 (unch)
Avanir Pharmaceuticals Announces Multiple Data Presentations Highlighting Its Central Nervous System (CNS) Therapeutics Franchise at the American Academy of Neurology (AAN) 2015 Annual Meeting
PR Newswire - Wed Apr 15, 8:55AM CDT
Avanir Pharmaceuticals, Inc. today announced that data highlighting its central nervous system (CNS) therapeutics franchise, including data from the Phase 2 study of AVP-923 for the treatment of agitation in Alzheimer's disease, data from the Alzheimer's cohort of PRISM II of NUEDEXTA® for the treatment of Pseudobulbar Affect (PBA) and several data presentations on the use of AVP-825 for the treatment of acute migraine, will be presented at the American Academy of Neurology (AAN) Annual Meeting being held at the Walter E. Washington Convention Center in Washington, D.C., April 18-25, 2015.
AVNR: 16.96 (unch)
Football Hall-of-Famer Barry Sanders Tackles Pseudobulbar Affect; A Little-known But Widespread Condition Caused by Brain Injury
PR Newswire - Wed Jan 21, 6:30AM CST
New research shows 99 percent of former professional football players surveyed by the Gridiron Greats Assistance Fund, Inc., have suffered a head injury, repeated concussions, or a blow to the head sometime during their football career. More concerning is that a third of these players admit to experiencing symptoms consistent with a little-known neurological condition caused by brain injury called Pseudobulbar Affect (PBA); and most were unaware that PBA symptoms may result from head injury. To help educate the community, legendary football Hall-of-Famer, Barry Sanders, has teamed up with Gridiron Greats and Avanir Pharmaceuticals, Inc. to launch Tackle PBA, a new educational campaign to increase awareness of PBA as a potential consequence of brain injury.
AVNR: 16.96 (unch)
The Surprising Thing Most of 2014's Top 10 Stocks Have in Common
Keith Speights, The Motley Fool - Motley Fool - Sun Jan 11, 9:03AM CST
Are you good at spotting patterns? Most of us are. We even spot patterns when they're really not there -- like seeing faces in clouds. The list below of 2014's top 10 stocks with a market cap above $300 million, however, reveals a very real pattern...
AVNR: 16.96 (unch), NPSP: 45.97 (+0.01), AGIO: 36.35 (-0.39), CELG: 105.49 (-0.88), EXEL: 11.54 (+0.19)
Avanir reports 4Q loss
Automated Insights - Mon Jan 05, 1:46PM CST
ALISO VIEJO, Calif. (AP) _ Avanir Pharmaceuticals Inc. (AVNR) on Wednesday said its loss narrowed to $14.1 million in its fiscal fourth quarter.
AVNR: 16.96 (unch)
The Market's Top 10 Stocks of 2014
Dan Caplinger, The Motley Fool - Motley Fool - Sat Jan 03, 8:00AM CST
For six years now, investors have looked with skepticism at the rise in the stock market. And for a sixth straight year, the markets defied those who were waiting for a major downturn to invest, with the S&P 500 climbing about 14% including...
BLUE: 49.05 (-0.28), TTPH: 3.72 (-0.06), AVNR: 16.96 (unch), SWKS: 74.62 (-0.47), CMRX: 4.62 (unch), ACHN: 8.12 (-0.11), HA: 47.60 (+0.31), RCPT: 231.96 (-0.03), PTCT: 7.91 (+0.12), AGIO: 36.35 (-0.39)
(0)
(0)Scroll down for more posts ▼